You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Dow

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

SOLUPREP Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Soluprep patents expire, and when can generic versions of Soluprep launch?

Soluprep is a drug marketed by 3m Health Care and is included in one NDA. There is one patent protecting this drug.

This drug has nine patent family members in seven countries.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

US ANDA Litigation and Generic Entry Outlook for Soluprep

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 8, 2021. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for SOLUPREP
International Patents:9
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 1
Formulation / Manufacturing:see details
DailyMed Link:SOLUPREP at DailyMed
Drug patent expirations by year for SOLUPREP
Generic Entry Opportunity Date for SOLUPREP
Generic Entry Date for SOLUPREP*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
NDA:
Dosage:
SOLUTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SOLUPREP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Maria-Virginia Rodriguez FunesPhase 4

See all SOLUPREP clinical trials

US Patents and Regulatory Information for SOLUPREP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
3m Health Care SOLUPREP chlorhexidine gluconate; isopropyl alcohol SOLUTION;TOPICAL 208288-001 Aug 8, 2018 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
3m Health Care SOLUPREP chlorhexidine gluconate; isopropyl alcohol SOLUTION;TOPICAL 208288-001 Aug 8, 2018 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
Harvard Business School
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.